In a retrospective study in a cohort of Japanese patients using the same diagnostic antibody and criteria for CLDN18.2 positivity, a concordance rate of 75.1% was reported between pair-matched tumor samples from 17 patients collected before and after 1L chemotherapy [21]. The gene discussed is CLDN18; the disease is neoplasm.